Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name	Generic Name	Therapeutic Area	Recommendation Type Sort ascending	Project Status	Date Submission Received	Date Recommendation Issued
Victoza	Liraglutide	Diabetes mellitus, Type 2	Do not list	Complete	Nov 29, 2010	Sep 28, 2011
Daxas	Roflumilast	Chronic obstructive pulmonary disease	Do not list	Complete	Nov 30, 2010	Jul 27, 2011
Restasis ophthalmic emulsion	Cyclosporine	Dry eye disease	Do not list	Complete	Dec 17, 2010	Jul 18, 2011
Celsentri	Maraviroc	HIV infection	Do not list	Complete	Dec 8, 2010	Jul 18, 2011
Nucynta CR	Tapentadol	Pain, moderate to moderately severe	Do not list	Complete	Feb 1, 2011	Sep 28, 2011
Zenhale (inhalation aerosol)	Mometasone furoate and formoterol	Asthma	Do not list	Complete	Feb 16, 2011	Sep 28, 2011
Revolade	Eltrombopag olamine	Chronic immune thrombocytopenic purpura	Do not list	Complete	Apr 26, 2011	Oct 24, 2011
Brilinta	Ticagrelor	Acute coronary syndromes	Do not list	Complete	Jun 1, 2011	Dec 16, 2011
BuTrans	Buprenorphine transdermal patch	Pain, moderate intensity persistent pain	Do not list	Complete	May 9, 2011	Sep 28, 2011
Iressa	Gefitinib	Cancer, Lung , non-small cell	Do not list	Complete	Dec 22, 2003	Jun 23, 2004

Last Updated : May 15, 2024